Cytosorbents.
company
- Reports this week
- 0
- Active events
- 0
- Connections
- 20
What's happening
One to three months ago
-
Cytosorbents regained the minimum bid price requirement of $1.00 per share on Nasdaq and is advancing its DrugSorb-ATR product toward FDA regulatory approval.Some support1 report
-
Cytosorbents held an investor conference in New York City.Some support1 report
-
The FDA upheld the De Novo denial for DrugSorb-ATR, a product of CytoSorbents. Phillip Chan serves as the company's CEO.Well supported7 reports
Gone quiet
No new reports in 90+ days-
Cytosorbents is facing market challenges in Germany and the Middle East, which CEO Phil Chan has addressed.Some support3 reports
-
Cytosorbents is conducting research and commercialization in the US and Germany.Speculative1 report
-
Sales growth for Cytosorbents was driven by Germany on August 14, 2025.Some support1 report
-
CytoSorbents will present at a conference on September 5, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Cytosorbents this week
News at the entities that move Cytosorbents most-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Cytosorbents
-
AstraZeneca OperationalSeveral companies, including AstraZeneca, Kraft Heinz, and Fifth Third Bancorp, transferred their stock listings to the NYSE.Moves Cytosorbents
-
Nasdaq StructuralAnthropic, developer of Claude Code, is seeking a listing on the Nasdaq Global Select Market.Moves Cytosorbents
-
New York City Shared contextAn auction of Creston Manor, a working winery near Paso Robles, concluded in New York City.Moves Cytosorbents
-
Middle East Shared contextThe Middle East conflict involving Iran continues, with Adam Smith criticizing Donald Trump's administration regarding its lack of transparency.Moves Cytosorbents
Connections
The 10 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Phillip Chan Structural
Phillip Chan holds the formal role of Chief Executive Officer of Cytosorbents.
-
FDA Structural
FDA regulates Cytosorbents' drug submissions, issuing denials and providing market authorization guidance.
-
Phil Chan Structural
Phil Chan serves as the CEO of Cytosorbents, establishing a leadership and functional dependency.
-
Tom Shannon Structural
Cytosorbents appointed Tom Shannon as VP of Marketing to lead marketing strategy for DrugSorb-ATR.
-
AstraZeneca Operational
Cytosorbents' drug product is clinically used alongside AstraZeneca's Brilinta in patients.
-
S. Lee Operational
S. Lee provides financial forecasts and analysis regarding Cytosorbents' earnings.
-
Nasdaq Structural
Cytosorbents must maintain minimum bid price requirements to remain listed on the Nasdaq exchange.
-
New York City Shared context
Cytosorbents holds an investor conference within New York City.
Show all 10 connections
-
Automated Insights Mentioned together
Automated Insights utilizes Cytosorbents' company data to generate financial stories and earnings snapshots.
-
Middle East Shared context
The evidence discusses the general business outlook of the Middle East but does not mention Cytosorbents.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
1 eventJune 2026
4 events- The FDA upheld the De Novo denial for DrugSorb-ATR, a product of CytoSorbents. Phillip Chan serves as the company's CEO.
- Cytosorbents is conducting research and commercialization in the US and Germany.
- Sales growth for Cytosorbents was driven by Germany on August 14, 2025.
- CytoSorbents will present at a conference on September 5, 2025.